Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594435 · ClinicalTrials.gov registry record · Phase 2
Ibudilast for the Treatment of Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT03594435: Completed Phase 2 study of Alcohol Use Disorder, sponsored by University of California, Los Angeles.
NCT03594435 is a Phase 2 study of Alcohol Use Disorder that has completed, run by University of California, Los Angeles. The registered enrollment target is 102 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03594435, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.
Primary Outcome
Heavy drinking days defined as 5+ drinks for men and 4+ for women. Reported outcome measures are proportions of heavy drinking days.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Ibudilast
Study Locations (1)
California
- UCLA Addictions Laboratory - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
What the finished NCT03594435 record still lists
NCT03594435 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03594435 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03594435 about?
NCT03594435 is a clinical study titled "Ibudilast for the Treatment of Alcohol Use Disorder". This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.
What is the current status of trial NCT03594435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2018-10-01. Estimated completion is 2023-04-19.
What conditions does trial NCT03594435 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT03594435?
The interventions under investigation include: Placebo oral capsule (DRUG), Ibudilast (DRUG).
Who is sponsoring clinical trial NCT03594435?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03594435 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03594435's enrollment target sits among peer trials
102 80th of 184 higher than 105 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI